It’s one of the most common questions patients ask before starting a medical weight loss program.
“What happens when I stop taking the medication?”
The answer depends on the individual.
Some patients are able to maintain their results through healthy habits and ongoing lifestyle changes. Others may find that their appetite gradually returns or that maintaining their goal weight becomes more challenging without continued medical support.
Research has shown that some people regain weight after stopping GLP-1 medications such as semaglutide, the active ingredient in Ozempic® and Wegovy®, and tirzepatide, the active ingredient in Mounjaro® and Zepbound®. That’s because these medications help regulate appetite and feelings of fullness while you’re taking them. When treatment ends, those effects may gradually diminish, making it easier for hunger to return.
This is one reason Pro Health approaches medical weight loss as more than simply prescribing medication.
Weight Loss Maintenance Looks Different for Everyone
Reaching your goal weight is an exciting milestone, but maintaining that success often requires just as much attention as losing the weight in the first place.
Healthy eating habits, regular physical activity, quality sleep, stress management, and continued accountability all play important roles in long-term success.
Some patients continue treatment for a period of time to help maintain their results, while others may eventually transition off medication under the guidance of their healthcare provider.
Every patient’s maintenance plan is different because every patient’s health history, goals, and lifestyle are different.
There Isn’t a Single Right Answer
Some individuals are able to maintain their weight after stopping semaglutide or tirzepatide.
Others may notice increased hunger or gradual weight regain over time.
That doesn’t mean treatment has failed.
Weight management is a lifelong process, and occasional adjustments are common. Your healthcare provider can help determine the approach that best supports your goals based on your progress and overall health.
For some patients, continuing treatment at a maintenance dose may be appropriate. Others may benefit from transitioning to another medically supervised option or focusing on nutrition, exercise, and other healthy lifestyle strategies that help maintain their progress.
Why Follow-Up Care Matters
One of the advantages of working with Pro Health is that your treatment doesn’t end once you’ve reached your goal.
Regular follow-up appointments allow your provider to evaluate your progress, discuss maintenance strategies, and adjust your plan as your needs change.
Whether you’re continuing medication, reducing your dosage, or transitioning off treatment altogether, ongoing medical supervision can help you navigate those changes with confidence.
This ongoing relationship helps patients feel supported through every stage of their journey.
Long-Term Success Is the Goal
Medical weight loss is about more than reaching a certain number on the scale.
The goal is to develop healthier habits that continue supporting your wellness long after treatment begins.
At Pro Health, our providers work with patients to create realistic plans that reflect both short-term goals and long-term success.
Whether that includes continued medication, a maintenance strategy, or another personalized approach, our team is here to help you build a plan that works for your lifestyle and health goals.
With five convenient Memphis-area clinics, Pro Health provides ongoing support before, during, and after your weight loss journey so you never have to navigate long-term success alone.
Important Disclosure
Semaglutide is the active ingredient in Ozempic® and Wegovy®. Tirzepatide is the active ingredient in Mounjaro® and Zepbound®.
Compounded semaglutide and compounded tirzepatide are compounded drug products that have not been approved by the U.S. Food and Drug Administration (FDA); have not been reviewed by the FDA for safety, effectiveness, or quality; and have not been demonstrated to the FDA to be safe or effective for their intended use. The manufacturing processes used to produce compounded medications have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company.